QNCX vs. INKT, ESLA, CYTH, SABS, ACHL, OKYO, PLUR, DYAI, BCLI, and SRZN
Should you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include MiNK Therapeutics (INKT), Estrella Immunopharma (ESLA), Cyclo Therapeutics (CYTH), SAB Biotherapeutics (SABS), Achilles Therapeutics (ACHL), OKYO Pharma (OKYO), Pluri (PLUR), Dyadic International (DYAI), Brainstorm Cell Therapeutics (BCLI), and Surrozen (SRZN). These companies are all part of the "biological products, except diagnostic" industry.
Quince Therapeutics (NASDAQ:QNCX) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends.
MiNK Therapeutics has a consensus target price of $9.00, indicating a potential upside of 791.09%. Given MiNK Therapeutics' higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Quince Therapeutics.
MiNK Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.
Quince Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.
MiNK Therapeutics' return on equity of 0.00% beat Quince Therapeutics' return on equity.
In the previous week, MiNK Therapeutics had 7 more articles in the media than Quince Therapeutics. MarketBeat recorded 11 mentions for MiNK Therapeutics and 4 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.87 beat MiNK Therapeutics' score of 0.48 indicating that Quince Therapeutics is being referred to more favorably in the media.
MiNK Therapeutics received 11 more outperform votes than Quince Therapeutics when rated by MarketBeat users.
30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by company insiders. Comparatively, 17.8% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
MiNK Therapeutics beats Quince Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Quince Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quince Therapeutics Competitors List
Related Companies and Tools
